Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Centogene Enter Drug Discovery Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Centogene Enter Drug Discovery Collaboration

Sign global partnership on drug discovery projects in rare genetic diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Centogene AG and Evotec have entered into a global strategic collaboration agreement for joint drug discovery projects focused on developing compounds to treat rare genetic diseases.

Evotec and Centogene initiated the collaboration to develop a strategic high-throughput platform for testing novel small molecules in rare hereditary metabolic diseases.

The collaboration brings together Evotec’s = induced pluripotent stem cell (iPSC) platform and broad drug discovery capabilities with Centogene’s medical and genetic insights. In particular, detailed genotype-phenotype data enables rapid biomarker development using patient primary cells.

“The collaboration between Evotec and Centogene is focused on developing iPSC-based patient-derived disease models and suitable biomarkers for rare genetic diseases,” said Cord Dohrmann, chief scientific officer, Evotec. “A perfect match between highly complementary platforms and companies with the potential to open a new chapter in the translatability of pre-clinical discovery efforts into clinic benefits.”

Arndt Rolfs, chief executive officer, Centogene, said, “The identification and development of innovative small molecules to treat rare, hereditary conditions is particularly challenging because of the absence of adequate cellular models and the general lack of specific biomarkers to monitor the different diseases. With this innovative collaboration between Evotec and Centogene, we can accelerate the development of new drugs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics